Pre-clinical studies are promising; for example, in a mouse model of ovarian cancer, the combination of DNMTi Decitabine with anti-CTLA-4 increased the recruitment of NK cells and CD8+ T cells and prolonged survival [154]. Here, CD8A is linked to ovarian cancer.